EBS FY 2020 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

FY 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.6B+42.6% YoY

Gross Profit

$863M54.7% margin

Operating Income

$439M27.8% margin

Net Income

$306M19.4% margin

EPS (Diluted)

$5.67

Cash Flow

Operating Cash Flow

$537M

Free Cash Flow

$395M

Stock-Based Comp.

$52M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.4B

Stockholders' Equity

$1.4B

Cash & Equivalents

$621M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.1B	+42.6%
Gross Profit	$863M	$483M	+78.7%
Operating Income	$439M	$114M	+284.3%
Net Income	$306M	$55M	+461.1%